Lumibird

Valuation Analysis

About the Company

Lumibird en bref

Lumibird (LBIRD.PA) is currently trading at 26,40 € with a market capitalization of 505 M €. The trailing P/E ratio stands at 41.25x, with a forward P/E of 20.95x. The 52-week range spans from 15,75 € to 28,50 €; the current price is 7.4% below the yearly high. Year-over-year revenue growth stands at +8.5%. The net profit margin stands at 6.13%.

💰 Dividende

Lumibird pays an annual dividend of 0,37 € per share, representing a yield of 1.4%.

📊 Avis des analystes

3 analystes évaluent Lumibird (LBIRD.PA) au consensus : Achat Fort. L'objectif de cours moyen est de 32,17 €, soit un potentiel de +21.84% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 30,00 € à 35,00 €.

Lumibird : la thèse d'investissement en détail

Lumibird (LBIRD.PA) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in France. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Earnings growth of 58.5% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 63.36%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 21.84% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

À surveiller

• The forward P/E of 20.95x is meaningfully below the trailing 41.25x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 21.84% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Lumibird?

Compare top-rated brokers — low fees, trusted providers, fully regulated.